奥沙利铂联合5-氟尿嘧啶及亚叶酸钙治疗老年晚期大肠癌患者的临床研究
被引量:4
摘要
结肠癌发病率在世界居恶性肿瘤第4位[1],约50%患者发生转移[2]。单用5-氟尿嘧啶(5-FU)在进展期肿瘤中其有效率大约仅为10%[3]。奥沙利铂(L-OHP)为二氨基环己烷基团铂类复合物,作用机制为抑制DNA复合物形成。单剂使用L-OHP对转移性结肠癌患者有效率可达到10%~24%[4]。
出处
《北京医学》
CAS
2012年第1期4-4,14,共2页
Beijing Medical Journal
参考文献6
-
1Leitch EF, Chakrabarti M, Crozier JEM, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer,2007,97: 1266-1270.
-
2Haydon AMM, MacInnis R J, English DR, et al. Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut,2006,55:62-67.
-
3Park JY, Kim SY, Lee JJ, et al. The efficacyof a modified chronomodulated infusion of oxaliplatin, 5 -fluorouracil and leucovofin in advanced colorectal cancer (preliminary data). Cancer Res Treat,2004,36:199-204.
-
4Hanna K, Sanoff, Daniel J. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol, 2008, 26:5721-5727.
-
5翟艳辉,李莹,杨朝英,黎苗,董瑜.草酸铂联合氟尿嘧啶、甲酰四氢叶酸治疗晚期大肠癌临床疗效观察[J].现代肿瘤医学,2006,14(1):65-67. 被引量:15
-
6孙燕,管忠震,金懋林,李维廉,李丽庆,石廷章,周立中,隋广杰,许立功,宋恕平,许德凤,李容,李扬,黄富麟,张嘉庆,张和平,鞠利雅.奥沙利铂单药或与氟尿嘧啶-甲酰四氢叶酸联合应用治疗晚期大肠癌Ⅱ期临床试用报告[J].癌症,1999,18(3):237-240. 被引量:344
二级参考文献9
-
1李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量:869
-
2[1]Maindrault Goebel F,De Gramont A,Louvet C,et al.High -dose intencity oxaliplatin added to the simplified bimonthly leuovorin and 5 - flourouracil regimen as second - line therapy for metastatic colorectal cancer (FOLFOX7) [J].Eur J Cancer,2001,37 (8):1000 ~ 1005.
-
3[2]Maindrault Goebel F,Louvet C,Andre T,et al.oxaliplatin added to the simplified bimonthly leucovorin and 5 - flourouracil regimen as second - line therapy for metastatic colorectal cancer (FOLFOX6)[J].Eur J Cancer,1999,35 (9):1338 ~ 1342.
-
4[4]De Gramont A,Louvet C,Andre T,et al.A review of GERCOD trials of bimonthly leucovorin plus 5 - flourouracil 48 - h continuous infusion in advanced colorectal cancer:evolution of a regimen[J].Eur J Cancer,1998,34(5) :619 ~626.
-
5[5]Bleiberg H.Oxaliplatin (L - OHP):a new reality in colorectal cancer[J].Br J Cancer,1998,77(4) :1 ~3.
-
6[6]Louvet C,De Gramant A.Role and value of oxaliplatin in metastatic colorectal cancers [J].Rev Med Interne,1997,18 (4):368 ~ 371.
-
7[7]De Gramont A,Vignoud J,Tournigand C,et al.Oxaliplatin with high - dose leucovorin and 5 - flourouracil 48 - hour continous infusion in pretreated matastatic colorectal cancer[J].Eur J Cancer,1997,33(1) :214 ~219.
-
8孙燕,临床肿瘤内科手术 第3版(第3版),1996年,33-101,214-215页
-
9孙燕,管忠震,金懋林,李维廉,李丽庆,石廷章,周立中,隋广杰,许立功,宋恕平,许德凤,李容,李扬,黄富麟,张嘉庆,张和平,鞠利雅.奥沙利铂单药或与氟尿嘧啶-甲酰四氢叶酸联合应用治疗晚期大肠癌Ⅱ期临床试用报告[J].癌症,1999,18(3):237-240. 被引量:344
共引文献354
-
1董人平,吴昌平.奥沙利铂加5-氟脲嘧啶、甲酰四氢叶酸联合治疗大肠癌临床观察与护理[J].当代护士(中旬刊),2003,10(5):40-42.
-
2刘春林,李元翠.奥沙利铂联合氟尿嘧啶持续泵注化疗的护理[J].临床医药实践,2007,16(12):1185-1186.
-
3张远博,金伟杰.奥沙利铂联合亚叶酸钙和氟尿嘧啶持续滴注治疗晚期大肠癌的临床观察[J].中国现代应用药学,2007,24(z1):646-647. 被引量:1
-
4李胜业,戴安伟.三维适形放疗同步化疗治疗直肠癌术后盆腔复发34例分析[J].中国误诊学杂志,2009,9(3):678-679.
-
5陈红宇,朱婷,鲍健.奥沙利铂与氟尿嘧啶 亚叶酸钙联合治疗晚期大肠癌的临床观察[J].安徽医学,2009,30(3):311-312. 被引量:2
-
6吴延杰.奥沙利铂联合氟尿嘧啶和亚叶酸钙治疗晚期结直肠癌的临床观察[J].中国实用医药,2007,2(13):103-96. 被引量:1
-
7苏思迹.奥沙利铂联合氟尿嘧啶、亚叶酸钙治疗晚期结直肠癌的疗效[J].中国医药导报,2006,3(35). 被引量:1
-
8魏玲,孙三元,孙丽.含羟基喜树碱联合方案静脉化疗联合腹腔化疗治疗晚期大肠癌的临床观察[J].中国医药导报,2005,2(15):37-38. 被引量:1
-
9朱红霞,应莹,周璟.乐沙定静脉化疗中2种不同方式所致副作用的对比研究及护理[J].当代护士(中旬刊),2004,11(12):43-44. 被引量:1
-
10白桦,郑瑾,王树滨,叶建增,徐敏,许瑞莲,陈亦欣,郑涛.伊立替康或奥沙利铂联合氟尿嘧啶及亚叶酸钙治疗晚期大肠癌[J].肿瘤研究与临床,2008,20(2):120-122. 被引量:2
同被引文献43
-
1赵亚恒.用奥沙利铂联合氟尿嘧啶和四氢叶酸钙治疗晚期大肠癌的疗效观察[J].求医问药(下半月刊),2012,10(12):613-614. 被引量:2
-
2彭波.5-氟尿嘧啶联合顺铂亚叶酸钙治疗晚期消化道癌的临床观察[J].山西医药杂志,2005,34(6):501-502. 被引量:2
-
3李悦,于雁.奥沙利铂联合氟尿嘧啶、亚叶酸钙联合治疗晚期消化道癌临床疗效分析[J].实用肿瘤学杂志,2006,20(6):525-526. 被引量:4
-
4朱东,刘小方,梁丕霞,徐有青.螺旋CT诊断老年大肠癌162例[J].世界华人消化杂志,2007,15(27):2951-2954. 被引量:5
-
5Hazra A,Fuchs CS,Kawasaki T,Kirkner GJ,Hunter DJ,Ogino S.Germline polymorphisms in the one-carbon metabolism pathway and DNA methylation in colorectal cancer.Cancer Causes Control 2010;21:331-345.
-
6Marrelli D,Roviello F,de Manzoni G,Morgagni P,Di Leo A,Saragoni L,De Stefano A,Folli S,Cordiano C,Pinto E.Different patterns of recurrence in gastric cancer depending on Lauren's histological type:longitudinal study.World J Surg 2002;26:1160-1165.
-
7Tournigand C,Cervantes A,Figer A,Lledo G,Flesch M,Buyse M,Mineur L,Carola E,Etienne PL,Rivera F,Chirivella I,Perez-Staub N,Louvet C,André T,Tabah-Fisch I,de Gramont A.OPTIMOX1:a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.J Clin Oncol 2006;24:394-400.
-
8Parkiri DM.Globale a neer statistics in the year 2000[J].Lancet Oncol,2001,2:533-543.
-
9Park JY,Kim SY,Lee JJ,et al.the efficacy of a modified chronomodulatedinfusion of oxaliplatin,5-fluorouracil and leucovorin in advanced colorec-tal cancer(preliminary data)[J].Cancer Res Treat,2004,36(3):199-204.
-
10Hanna K,Sanoff,Daniel J.Five-year data and prognostic factor analysisof oxaliplatin and irinotecan combinations for advanced colorectral cancer:N9741[J].J Clin Oncol,2008,26(13):5721-5727.
引证文献4
-
1姚彪,徐润,魏万高,商妮娅,杨丽芬.奥沙利铂联合氟尿密啶、亚叶酸钙治疗转移性大肠癌的临床疗效[J].世界华人消化杂志,2014,22(1):149-152. 被引量:11
-
2王大荣,王萍,刘静.艾迪注射液联合奥沙利铂治疗老年晚期大肠癌的临床疗效[J].实用临床医药杂志,2014,18(11):111-113. 被引量:5
-
3张洁.奥沙利铂联合氟尿嘧啶及亚叶酸钙治疗转移性大肠癌120例疗效评价[J].中国药业,2014,23(23):19-21. 被引量:6
-
4刘禹,黄蔚,杨智岗,黄海.奥沙利铂联合氟尿密啶、亚叶酸钙治疗转移性大肠癌的临床疗效研究[J].现代消化及介入诊疗,2018,23(2):218-220. 被引量:2
二级引证文献23
-
1王磊.爱迪注射液联合奥沙利铂治疗老年晚期大肠癌的疗效和安全性[J].糖尿病天地,2018,15(10):84-84.
-
2谭小浪,郭磊.不同化疗方案对大肠癌患者淋巴细胞亚群的影响[J].中国现代医药杂志,2014,16(9):54-56.
-
3杨倩,吴磊.奥沙利铂联合氟尿密啶和亚叶酸钙治疗转移性大肠癌的疗效观察[J].中国处方药,2014,12(9):37-37. 被引量:1
-
4张洁.奥沙利铂联合氟尿嘧啶及亚叶酸钙治疗转移性大肠癌120例疗效评价[J].中国药业,2014,23(23):19-21. 被引量:6
-
5张洁,班丽英.贝伐珠单抗联合化疗治疗晚期大肠癌的临床疗效[J].世界华人消化杂志,2015,23(10):1674-1678. 被引量:4
-
6何瑷年.临床护理路径对提高结直肠癌患者FOLFOX化疗依从性的效果[J].中国医药导报,2015,12(13):165-168. 被引量:14
-
7王建军,刘大晗.开普拓联合5-氟尿嘧啶治疗对5-氟尿嘧啶耐药晚期大肠癌的临床效果[J].世界华人消化杂志,2015,23(14):2341-2345. 被引量:4
-
8邓杰,吴志勇,赵海清,伍建宇.注射用奥沙利铂致发热1例[J].中国药物应用与监测,2015,12(3):191-193.
-
9龚海健.奥沙利铂联合氟尿密啶、亚叶酸钙治疗转移性大肠癌的临床疗效[J].中国医药指南,2015,13(29):184-185. 被引量:3
-
10袁青柳.OXA-LV5FU2方案治疗晚期胃癌60例疗效观察及护理对策[J].中国药业,2015,24(23):218-220. 被引量:1